Elekta nets FDA 510(k) clearance for VMAT
Elekta has received FDA 510(k) clearances for its Elekta VMAT solution designed for radiation oncology.
Elekta is uniquely positioned to introduce the volumetric modulated arc therapy (VMAT) technique by virtue of Elekta Synergy, a digital linear accelerator with integrated high-resolution 3D x-ray volume imaging. With daily pre-treatment imaging scans, clinicians who implement Elekta VMAT will be able to maximize accuracy and shrink treatment margins, while minimizing the possibility of damage to surrounding healthy tissue.
“More than ten years of research in collaboration with members of the Elekta IMRT Consortium has lead to this unique series of innovations,” explains Tomas Puusepp, president and CEO of Elekta. “Having the world’s only fully digital accelerator is a key element in making this level of automation and control complexity possible in a way that allows clinicians to deliver advanced treatments with a single push of a button.”
Elekta is uniquely positioned to introduce the volumetric modulated arc therapy (VMAT) technique by virtue of Elekta Synergy, a digital linear accelerator with integrated high-resolution 3D x-ray volume imaging. With daily pre-treatment imaging scans, clinicians who implement Elekta VMAT will be able to maximize accuracy and shrink treatment margins, while minimizing the possibility of damage to surrounding healthy tissue.
“More than ten years of research in collaboration with members of the Elekta IMRT Consortium has lead to this unique series of innovations,” explains Tomas Puusepp, president and CEO of Elekta. “Having the world’s only fully digital accelerator is a key element in making this level of automation and control complexity possible in a way that allows clinicians to deliver advanced treatments with a single push of a button.”